Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.36 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3850089 | 0.89 | RAB9A (0.39) | TAAR1MAPK1 | |
| SCHEMBL3851351 | 0.83 | TAAR1 (0.44) | TAAR1IDO1MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL17351838 | 0.82 | IDO1 (0.41) | TAAR1IDO1NFE2L2ACHECYP1A2 | |
| SCHEMBL10290674 | 0.79 | TAAR1 (0.43) | TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL8239069 | 0.79 | TAAR1 (0.43) | TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL14194626 | 0.78 | IDO1 (0.46) | TAAR1IDO1AMY1AACHECYP1A2 | |
| SCHEMBL268462 | 0.77 | TAAR1 (0.42) | TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL268243 | 0.77 | MAPK1 (0.54) | TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL583371 | 0.77 | TAAR1 (0.52) | TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL8574537 | 0.77 | TAAR1 (0.42) | TAAR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579342-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA (SE) | 2009-08-25 | — | — | US | disclosed |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | TAAR1 3194/4885IDO1 148/4885MAPK1 2143/4885 |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | TAAR1 3194/4885IDO1 148/4885MAPK1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.